Medical Article

This new standard was developed to address the rise of telehealth, cybersecurity risks/compliance in ePrescribing, data needs, AI, and the growing demand for patient transparency. So what is the Standard solving for, and what can providers expect? The post What Providers Need to Know About the Coming NCPDP Transition appeared first on MedCity News.

Novartis’s alliance with Unnatural Products is pursuing next-generation peptide drugs for cardiovascular disease. The startup already has drug R&D alliances with BridgeBio Pharma, Merck, and Argenx. The post Novartis Commits $100M to Startup With Tech That Brings Peptides to Undruggable Targets appeared first on MedCity News.

Regeneron Pharmaceuticals’ multiple myeloma drug linvoseltamab has clinical trial results showing complete responses in 90% of patients who have light chain amyloidosis, a rare blood disease. The preliminary data were presented during the annual meeting of the American Society of Clinical Oncology. The post Regeneron Cancer Drug Shows New Promise in a Rare Disease… and…

GSK’s Exdensur requires just two injections a year to treat severe asthma. Less frequent injections give this new biologic medicine a dosing edge over one of GSK’s own blockbuster respiratory products as well as severe asthma drugs from companies such as AstraZeneca, Sanofi, and Amgen. The post GSK Gets FDA Approval for New Severe Asthma…

One Phase 3 test of Auvelity met its main goal in Alzheimer’s agitation while the drug’s other pivotal trial showed numerical improvement that fell short of statistical significance. Axsome Therapeutics aims to offer an alternative to Rexulti, a Lundbeck and Otsuka Pharmaceutical product that is the only FDA-approved Alzheimer’s agitation drug. The post Axsome Aims…

Health insurance claims are a growing headache for providers; many say their employers could do more to help them address the daily demands of insurers The post How Healthcare Employers Can Do More To Help Providers Manage Payer Frustration appeared first on MedCity News.